–
Статьи в журналах
-
- 2022 Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
- Merseburger Axel S., Attard Gerhardt, Åström Lennart, Matveev Vsevolod B., Bracarda Sergio, Esen Adil, Feyerabend Susan, Senkus Elżbieta, López-Brea Piqueras Marta, Boysen Gunther, Gourgioti Georgia, Martins Karla, Chowdhury Simon
- в журнале Lancet Oncology, издательство The Lancet Publishing Group (United Kingdom), том 23, № 11, с. 1398-1408 DOI